Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Kelly

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Leukemia|August 20, 2024
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trialCarlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, et al.
Cancers|September 27, 2025
Harnessing p97/VCP: A Transformative AAA+ ATPase Target for Next-Generation Cancer TherapeuticsMaria Janina Carrera Espinoza, Sarah K Tucker, Sruthi Sureshkumar, et al.
Journal of Clinical Pathology|May 25, 2011
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsyRonan T Swords, Javier Anguita, Russell A Higgins, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Leukemia & Lymphoma|October 17, 2019
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignanciesTanya Siddiqi, Paul Frankel, Jan H Beumer, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2023
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T Nawrocki, Julian Olea, Claudia Villa Celi, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Leukemia|August 20, 2024
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trialCarlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, et al.
Cancers|September 27, 2025
Harnessing p97/VCP: A Transformative AAA+ ATPase Target for Next-Generation Cancer TherapeuticsMaria Janina Carrera Espinoza, Sarah K Tucker, Sruthi Sureshkumar, et al.
Journal of Clinical Pathology|May 25, 2011
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsyRonan T Swords, Javier Anguita, Russell A Higgins, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Leukemia & Lymphoma|October 17, 2019
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignanciesTanya Siddiqi, Paul Frankel, Jan H Beumer, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2023
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T Nawrocki, Julian Olea, Claudia Villa Celi, et al.
Pageof 5